Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.

Abstract: A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex or the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.

Abstract: Provided are novel fully human monoclonal antibodies that bind to human LAG-3. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-LAG-3 antibodies, expression vectors and host cells used for the expression of anti-LAG-3 antibodies. The invention further provides the methods for validating the function of antibodies in vitro. The antibodies of invention provide a potent agent for the treatment of multiple cancers via modulating human immune function.

Abstract: The present disclosure provides anti-EGFR antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: A Raman spectroscopy integrated perfusion cell culture system for monitoring and auto-controlling perfusion cell culture, comprising: a bioreactor, comprising: (1) an interior chamber for receiving a cell culture, (2) a port for feeding nutrient materials from a feed reservoir into the interior chamber, (3) a port for auto-bleeding from the interior chamber, and (4) a port for continuously harvesting materials from the interior chamber with the help of a cell retention system; a Raman analyzer, comprising (i) one or more Raman probes which are immersed into the bioreactor and is configured to collect Raman spectrum in the bioreactor, and (ii) a host computer which is configured to receive the Raman spectrum collected and transferred by the Raman probe and turn it into values; and a controller in communication with the Raman analyzer, the feed reservoir and an auto-bleeding device, the controller being configured to receive the values from the Raman analyzer and compare them with preset parameters, based on re

Abstract: Provided are a genetically modified cell line producing a recombinant glycoprotein having a mannose-terminated N-glycan and a method for producing the recombinant glycoprotein or a method for generating the cell, clone or cell line. The cell line comprises an insertion of less than 600 bp in the coding region of a chromosomal sequence encoding MGAT1.

Abstract: The present disclosure provides anti-LAG-3 heavy-chain antibody or the antigen-binding domain thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells.

Abstract: Provided is a polypeptide, comprising, from N-terminus to C-terminus, a) at least a variable region of a heavy chain of a heavy-chain antibody (VHH domain) that binds protein Programmed Death Ligand 1 (PD-L1), operably linked to IgG Fc binding domain; and b) human TGF?RII, or a fragment thereof capable of binding TGF?. An antibody comprises the said polypeptide, the amino acid sequences of the said antibody, cloning or expression vectors, cells and methods for expressing or isolating the antibodies are further provided. Therapeutic compositions comprising the said antibodies, and the methods for treating cancers and other diseases with the bispecific antibodies are also provided.

Abstract: Provided are a method and a system for culturing cells and harvesting biologics. More particularly process for cell culture by intensified perfusion with continuous harvest and without cell bleeding is provided.

Abstract: The present disclosure provides anti-CD19 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: A Raman spectroscopy integrated perfusion cell culture system for monitoring and auto-controlling perfusion cell culture, comprising: a bioreactor, comprising: (1) an interior chamber for receiving a cell culture, (2) a port for feeding nutrient materials from a feed reservoir into the interior chamber, (3) a port for auto-bleeding from the interior chamber, and (4) a port for continuously harvesting materials from the interior chamber with the help of a cell retention system; a Raman analyzer, comprising (i) one or more Raman probes which are immersed into the bioreactor and is configured to collect Raman spectrum in the bioreactor, and (ii) a host computer which is configured to receive the Raman spectrum collected and transferred by the Raman probe and turn it into values; and a controller in communication with the Raman analyzer, the feed reservoir and an auto-bleeding device, the controller being configured to receive the values from the Raman analyzer and compare them with preset parameters, based on re

Abstract: The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.

Abstract: A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.

Abstract: Provided in the present disclosure are anti-TIM-3 antibodies, the methods of hybridoma generation, the nucleic acid molecules encoding the anti-TIM-3 antibodies, expression vectors and host cells used for the expression of anti-TIM-3 antibodies. The disclosure further provides the methods for validating the function of antibodies in vitro and the efficacy of antibodies in vivo. The antibodies of the disclosure provide a very potent agent for the treatment of cancers via modulating immune functions.

Abstract: The present disclosure provides monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which can block the binding of PCSK9 to low-density lipoprotein (LDL) receptor, and therefore lower the level low-density lipoprotein cholesterol (LDL-C). The antibodies of disclosure provide very potent agents for the treatment of multiple Cardiovascular diseases (CVDs).

Abstract: The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

Abstract: Anti-LAG-3/PD-1 bispecific antibody molecules, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof are provided.